At the news
? BULLISHIMPACT 7/10 8-K filed May 27, 2026 at 06:37 ET
Apogee Therapeutics announced positive 16-week induction dose optimization results from Part B of the Phase 2 APEX trial of zumilokibart in moderate-to-severe atopic dermatitis. The mid-dose met all primary and secondary endpoints with high statistical significance (EASI-75 65.9% vs 23.4% placebo, p<0.001), supporting planned Phase 3 initiation in 2H 2026. The company also disclosed a strategic financing collaboration with Blackstone Life Sciences expected to provide funding through commercialization without need for future equity financing.
- APEX Part B met primary endpoint: mid-dose EASI-75 65.9% vs placebo 23.4% (p<0.001)
- Mid-dose secondary endpoints all met: IGA 0/1 46.0% (p<0.001), EASI-90 47.4% (p<0.001), I-NRS4 50.5% (p<0.001), EASI-100 16.5% (p<0.01), vLDA 20.6% (p<0.01)
- Mid-dose selected as planned Phase 3 dose; Phase 3 ADventure program (3 trials) expected to initiate 2H 2026
- Blackstone collaboration provides up to $1.3B in funding including $400M pre-approval and up to $400M approval tranche; max royalty rate 6.25% on up to $5B of WW annual sales
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access